Eli Lilly Says Foundayo Shows Promise in Treating Sleep Apnea
By Connor Hart
Eli Lilly said its oral weight-loss drug Foundayo significantly reduced the severity of obstructive sleep apnea in a late-stage clinical program, potentially expanding the drug's use beyond obesity treatment.
The pharmaceutical company on Monday said Foundayo met its primary endpoint in the recent study, reducing the frequency of breathing interruptions during sleep in adults with moderate-to-severe obstructive sleep apnea, and obesity or are overweight.
Eli Lilly said it plans to submit the results to the Food and Drug Administration by the end of the year, seeking approval for Foundayo to treat sleep apnea.
Shares climbed 3.1%, to $1,396.02, in morning trading.
Obstructive sleep apnea is a common complication of obesity and is closely linked to cardiovascular disease, said Thomas Seck, senior vice president of product development for Lilly Cardiometabolic Health.
The program showed that Foundayo improved sleep apnea and several cardiovascular risk factors, Seck said, highlighting the drug's potential to address conditions that contribute to heart disease.
"Foundayo is already making a difference for people living with obesity, and with plans to submit these results to the FDA by the end of the year, we could have the opportunity to help people living with obstructive sleep apnea," he said.
Foundayo reduced breathing interruptions during sleep by about 44% among patients not using positive airway pressure, or PAP, therapy and by nearly 28% among those using the treatment, Eli Lilly said. At 52 weeks, roughly 32%% of patients not using PAP and nearly 20% of those using it achieved remission or mild disease, the company added.
The drug's overall safety and tolerability profile was generally consistent with previous trials, with the most common adverse events being mild-to-moderate gastrointestinal effects, Eli Lilly said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 09, 2026 10:38 ET (15:38 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
4 Big Impacts from the US Midterm Elections for Investors
3 of the Best Dividend Stocks to Own
3 Stocks to Sell and 3 Stocks to Buy for November
United States